| 12448613 |
Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene |
Jackie L. Smith, Clayton Beard |
2025-10-21 |
|
| 12351839 |
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
James Jefferson Smith |
2025-07-08 |
|
| 12338444 |
Methods for producing a complex transgenic trait locus |
Andrew Mark Cigan, Saverio Carl Falco, Huirong Gao, Michael Lassner, Zhongsen Li +3 more |
2025-06-24 |
|
| 12006522 |
Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene |
Gary Owens, Janel Lape, James Jefferson Smith, John C. Morris, Caitlin Turner +1 more |
2024-06-11 |
$1,635,000 |
| 11993793 |
Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene |
Gary Owens, Janel Lape, James Jefferson Smith, John C. Morris, Caitlin Turner +1 more |
2024-05-28 |
$1,864,000 |
| 11753630 |
Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene |
Gary Owens, Janel Lape, James Jefferson Smith, John C. Morris, Caitlin Turner +1 more |
2023-09-12 |
$822,000 |
| 11680254 |
Engineered meganucleases specific for recognition sequences in the PCSK9 gene |
Victor Bartsevich, James Jefferson Smith, Janel Lape |
2023-06-20 |
$1,289,000 |
| 11459576 |
Methods for producing a complex transgenic trait locus |
Andrew Mark Cigan, Saverio Carl Falco, Huirong Gao, Michael Lassner, Zhongsen Li +3 more |
2022-10-04 |
|
| 11286291 |
Co-stimulatory domains for use in genetically-modified cells |
Aaron Martin, Jeffrey Sunman, Daniel T. MacLeod |
2022-03-29 |
$2,896,000 |
| 11278632 |
Engineered nucleases useful for treatment of hemophilia A |
James Jefferson Smith, Victor Bartsevich, Clayton Beard, Michael G. Nicholson |
2022-03-22 |
$3,053,000 |
| 11274285 |
Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome |
James Jefferson Smith |
2022-03-15 |
$2,895,000 |
| 11266693 |
Nucleic acids encoding engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene |
Michael G. Nicholson, James Jefferson Smith, Victor Bartsevich, Daniel T. MacLeod, Jeyaraj Antony |
2022-03-08 |
$1,769,000 |
| 11268065 |
Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene |
James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich |
2022-03-08 |
$1,769,000 |
| 11053484 |
Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene |
James Jefferson Smith, Clayton Beard |
2021-07-06 |
$13,679,000 |
| 10851358 |
Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
James Jefferson Smith |
2020-12-01 |
$13,423,000 |
| 10822610 |
Methods for producing a complex transgenic trait locus |
Andrew Mark Cigan, Saverio Carl Falco, Huirong Gao, Michael Lassner, Zhongsen Li +3 more |
2020-11-03 |
|
| 10800833 |
Co-stimulatory domains for use in genetically-modified cells |
Aaron Martin, Daniel T. MacLeod |
2020-10-13 |
$4,266,000 |
| 10799535 |
Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene |
Michael G. Nicholson, James Jefferson Smith, Victor Bartsevich, Daniel T. MacLeod, Jeyaraj Antony |
2020-10-13 |
$4,266,000 |
| 10758595 |
Treatment of retinitis pigmentosa using engineered meganucleases |
Victor Bartsevich, James Jefferson Smith, Michael G. Nicholson |
2020-09-01 |
$6,583,000 |
| 10745665 |
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
Joann Hux, Aaron Martin, Clayton Beard |
2020-08-18 |
$7,570,000 |
| 10662416 |
Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
James Jefferson Smith |
2020-05-26 |
$4,408,000 |
| 10662440 |
Self-limiting viral vectors encoding nucleases |
James Jefferson Smith, Michael G. Nicholson |
2020-05-26 |
$4,408,000 |
| 10603363 |
Treatment of retinitis pigmentosa using engineered meganucleases |
Victor Bartsevich, James Jefferson Smith, Michael G. Nicholson |
2020-03-31 |
$7,023,000 |
| 10287626 |
Recognition sequences for I-CreI-derived meganucleases and uses thereof |
James Jefferson Smith |
2019-05-14 |
$10,999,000 |
| 10273524 |
Recognition sequences for I-CreI-derived meganucleases and uses thereof |
James Jefferson Smith |
2019-04-30 |
$11,332,000 |
